Stephen Poor

Company: Novartis Institutes for Biomedical Research

Job title: Director External Opportunities & Translational Biomarkers

Seminars:

An Update & Analysis of the Macular Degeneration Complement Landscape 2:30 pm

Assessing the current status of complement therapeutics in clinical development What are the implications of month 24 Phase 3 data from APELLIS and Month 12 Phase 3 data from IVERIC for geographic atrophy treatment ( intravitreal C3 and C5 therapy)? What is the potential of gene therapy and systemic approaches in clinical development vs intravitreal…Read more

day: Track B - Day 1 PM